NARSAD Grants Help Ease The Transition From Clinical Training To Basic Research

Making the transition from clinical training to basic research can be difficult for a young scientist; it's almost like starting a new career. With no research track record, getting established and obtaining funding loom as monumental tasks. This was the prospect facing William Honer when he finished his psychiatry residency at Columbia University. Fortunately for Honer and others like him in the field of psychiatry, assistance was available. The Chicago-based National Alliance for Research on

Written byLisa Bain
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

This was the prospect facing William Honer when he finished his psychiatry residency at Columbia University. Fortunately for Honer and others like him in the field of psychiatry, assistance was available. The Chicago-based National Alliance for Research on Schizophrenia and Depression (NARSAD) had begun only a year earlier, in 1987, to award Young Investigator grants to budding scientists.

"We want to stimulate the careers of bright, young people coming in," says Herbert Pardes, president of NARSAD's scientific council and director of the National Institute of Mental Health (NIMH) from 1978 to 1984. NARSAD tries to fill in the gaps in the NIMH funding system with a streamlined application process. "We try to make this organization as consumer-friendly as possible by minimizing paperwork [and] maximizing flexibility as to what they may do with the money, and we try to be supportive," says Pardes.

Young investigators, defined by NARSAD as scientists from ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies